REMARKS

Applicant hereby elects to prosecute hepatocellular carcinoma cells species for composition of claim 103 (paragraph 2 of the October 18, 2002 Restriction Requirement). Further, Applicant hereby elects to prosecute 4-1BB positive cells species (paragraph 3 of the October 18, 2002 Restriction Requirement) and antibodies against 4-1BB positive cells species (paragraph 5 of the October 18, 2002 Restriction Requirement) for composition of claim 103. Finally, Applicant hereby elects to prosecute TNF-alpha treated cells and IFN-gamma treated cells species for composition of claim 103 (paragraphs 4 and 6 of the October 18, 2002 Restriction Requirement).

For the Examiner's convenience, Applicant has submitted a listing of claims 103, 107-119, 121-137 and 140-143 readable on the elected species in Exhibit A.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532732000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: November 18, 2002

Respectfully submitted,

By: _____

Peng Chen
Registration No. 43,543

Morrison & Foerster LLP
3811 Valley Centre Drive, # 500
San Diego, CA 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125

EXHIBIT A

Pending claims for 08/872,527 readable on species election

103. (Amended) An isolated, enriched or purified immunogenic composition comprising:

one or more autologous target carcinoma or lymphoma cells which have been irradiated and treated in vitro wherein said target carcinoma or lymphoma cells express one or more primary or costimulatory T cell activation molecules at a level higher than the amount of primary or costimulatory T cell activation molecules expressed from carcinoma or lymphoma cells without treatment in a patient mammal;

one or more antibodies wherein said antibodies further bind to an antigenic binding site on the surface of said one or more target carcinoma or lymphoma cells;

one or more primary or costimulatory T cell activation molecules on the surface of T cells in said patient mammal; and

a bridge molecule binding said antibodies and said primary or costimulatory T cell activation molecules on the surface of T cells of said patient mammal.

107. The composition of claim 103, wherein said one or more hepatocellular carcinoma, lymphoma or colorectal carcinoma cells comprise one or more hepatocellular carcinoma cells.

108. The composition of claim 103, wherein said one or more hepatocellular carcinoma, lymphoma or colorectal carcinoma cells comprise one or more lymphoma cells.

109. The composition of claim 103, wherein said one or more hepatocellular carcinoma, lymphoma or colorectal carcinoma cells comprise one or more colorectal carcinoma cells.

110. The composition of claim 103, wherein said one or more CD28 or 4-1BB molecules comprise one or more CD28 molecules.

111. The composition of claim 103, wherein said one or more CD28 or 4-1BB molecule comprise one or more 4-1BB molecules.

112. The composition of claim 103, wherein said one or more hepatocellular carcinoma or colorectal carcinoma cells express said one or more CD28 or 4-1BB molecules at a level 50% higher than the amount that said one or more CD28 or 4-1BB molecules are expressed from hepatocellular carcinoma, lymphoma or colorectal carcinoma cells in a patient mammal.

113. The composition of claim 103, wherein said hepatocellular carcinoma or colorectal carcinoma cell expresses said one or more CD28 or 4-1BB molecules at a level 2 fold higher than the amount that said one or more CD28 or 4-1BB molecules are expressed from hepatocellular carcinoma or colorectal carcinoma cells in a patient mammal.

114. The composition of claim 103, wherein said hepatocellular carcinoma, lymphoma or colorectal carcinoma cell expresses said one or more CD28 or 4-1BB molecules at a level 10 fold higher than the amount that said one or more CD28 or 4-1BB molecules are expressed from hepatocellular carcinoma, lymphoma or colorectal carcinoma cells in a patient mammal.

115. The composition of claim 103, wherein said patient mammal is a human.

116. The composition of claim 103, wherein the one or more target hepatocellular carcinoma, lymphoma or colorectal carcinoma cells are treated with IFN-γ.

117. The composition of claim 103, wherein the one or more target hepatocellular carcinoma, lymphoma or colorectal carcinoma cells are treated with TNF-α.

118. The composition of claim 103, wherein the one or more target hepatocellular carcinoma, lymphoma or colorectal carcinoma cells are treated with IFN-γ and TNF-α.

119. The composition of claim 103, wherein said antibody is a bispecific or multispecific monoclonal antibody.

121. The composition of claim 103, wherein substantially all of said antibodies are attached to said hepatocellular carcinoma, lymphoma or colorectal carcinoma cells.

122. The composition of claim 103, wherein over 80% of said antibodies are attached to said hepatocellular carcinoma, lymphoma or colorectal carcinoma cells.

123. The composition of claim 103, wherein over 90% of said antibodies are attached to said hepatocellular carcinoma, lymphoma or colorectal carcinoma cells.

124. The composition of claim 103, wherein over 95% of said antibodies are attached to said hepatocellular carcinoma, lymphoma or colorectal carcinoma cells.

126. The composition of claim 103, wherein a pharmaceutically effective amount of said antibodies are bound to said hepatocellular carcinoma, lymphoma or colorectal carcinoma cells.

127. The composition of claim 103, further comprising a pharmaceutically acceptable carrier or excipient.

128. The composition of claim 103, wherein at least one of said hepatocellular carcinoma, lymphoma or colorectal carcinoma cells has attached thereto a plurality of said antibodies.

129. The composition of claim 103, wherein said antibodies comprise two or more antigen binding sites for one or more gp55 antigens on the surface of said one or more target hepatocellular carcinoma, lymphoma or colorectal carcinoma cells.

130. The composition of claim 103, wherein said antibodies comprise two or more binding sites for said one or more CD28 or 4-1BB molecules on the surface of T cells in said patient mammal.

131. The composition of claim 103, wherein said composition comprises two or more antibodies comprising one or more antigen binding sites for one or more gp55 antigens on the surface of said one or more target hepatocellular carcinoma, lymphoma or colorectal carcinoma cells.

132. The composition of claim 103, wherein said composition comprises two or more antibodies each comprising a binding site for a different one of said CD28 or 4-1BB molecules.

133. The composition of claim 103, wherein said composition comprises two or more antibodies each attached to a different antigen.

134. The composition of claim 103, further comprising a pharmaceutically effective amount of IFN-γ, TNF-α, or both.

135. The composition of claim 103, wherein said hepatocellular carcinoma, lymphoma or colorectal carcinoma cells are treated with 10-100 U of IFN-γ and 10-100 U of TNF-α.

136. The composition of claim 103, wherein said hepatocellular carcinoma, lymphoma or colorectal carcinoma cells are treated with 100 U of IFN-γ and 50 U of TNF-α.

137. The composition of claim 107, wherein said hepatocellular carcinoma cells are hepa 1-6 cells.

140. The composition of claim 103, wherein said target carcinoma cells further comprise hepatocellular carcinoma or colorectal carcinoma cells.

141. The composition of claim 103, wherein said antibodies further comprise one or more binding sites for antigen gp55.

142. The composition of claim 103, wherein said primary or costimulatory T cell activation molecules bind to CD28 or 4-1BB.

143. The composition of claim 103, wherein said bridge molecule further comprises bispecific monoclonal antibody.